NCT06835972View on ClinicalTrials.gov

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma
Interventions
DRUG

Abemaciclib

twice a day, orally

DRUG

Cabozantinib

once daily, orally

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York

10604

RECRUITING

Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack

21287

NOT_YET_RECRUITING

Johns Hopkins University (Data Collection Only), Baltimore

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Exelixis

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT06835972 - A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Biotech Hunter | Biotech Hunter